The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
VJVirtual | Defining lymphoma reservoirs
Jessica Okosun, MA, MB, BChir, PhD, MRCP, FRCPath, Barts Cancer Institute, London, UK, discusses one of the key clinical challenges for indolent lymphomas – relapse following initial treatment response. Ongoing research has shown that following induction treatment a minimal residual disease population or lymphoma reservoir is left behind. Research into the biology of these reservoirs is vital to move towards preventing further relapse or transformation, particularly in follicular lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
